<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927485</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol A2210108-UPR</org_study_id>
    <nct_id>NCT00927485</nct_id>
  </id_info>
  <brief_title>Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)</brief_title>
  <official_title>Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Puerto Rico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Puerto Rico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial Adenomatous Polyposis (FAP) is an autosomal dominant disorder characterized by the&#xD;
      formation of multiple adenomatous colorectal polyps usually in the teenage years. Virtually,&#xD;
      all patients with FAP will develop colorectal cancer on average by the 5th decade of life if&#xD;
      prophylactic surgery is not performed. Besides, these individuals must have lifelong cancer&#xD;
      surveillance of the remaining colorectum or ileum.&#xD;
&#xD;
      Use of nonsteroidal anti-inflammatory drug (NSAID), such as sulindac, or celecoxib, which&#xD;
      selectively inhibits prostaglandin synthesis primarily via the inhibition of cyclogenase-2&#xD;
      (COX-2) have been shown to reduce the incidence and induce regression of adenomas in the&#xD;
      rectum of patients with FAP. However, use of NSAIDs and COX-2 inhibitors is associated with&#xD;
      significant comorbidity including renal and gastric toxicity and increased risk of vascular&#xD;
      events. Therefore, identification of a chemopreventive agent that would have similar efficacy&#xD;
      but less toxicity would enhance our ability to treat these patients. Therefore the following&#xD;
      specific aim has been proposed:To determine in a randomized, double-blinded,&#xD;
      placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal&#xD;
      adenomas by measuring duodenal and colorectal/ileal polyp number, and polyp size in patients&#xD;
      with FAP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to curcumin (2 curcumin pills twice a day for 12 months) or&#xD;
      placebo (2 pills twice a day for 12 months). Besides, blood samples, risk factor&#xD;
      questionnaire,and biopsies (upper endoscopy and sigmoidoscopy) will be obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2007</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Polyps</measure>
    <time_frame>5 years</time_frame>
    <description>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number in patients with FAP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Size of Polyps</measure>
    <time_frame>5 years</time_frame>
    <description>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp size in patients with FAP.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pills)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcumin (Curcumin)</intervention_name>
    <description>Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Curcumin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Risk Factor Questionnaire</intervention_name>
    <description>Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Three tubes of blood at visits 0, 4 and 12 months.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies (Sigmoidoscopy)</intervention_name>
    <description>Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biopsies (Upper endoscopy)</intervention_name>
    <description>Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21-85 years with FAP (with an intact colon or who have had surgery)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mentally incompetent&#xD;
&#xD;
          -  Female patients of childbearing age not on effective birth control&#xD;
&#xD;
          -  Patients with WBC &lt; 3,500/ml, platelet count &lt; 100,000/ml, BUN &gt; 25mg%, creatinine &gt;&#xD;
             1.5mg%&#xD;
&#xD;
          -  Patients unable to stop NSAIDS or aspirin use for the duration of the study&#xD;
&#xD;
          -  Malignancy other than nonmelanoma skin cancer&#xD;
&#xD;
          -  Active bacterial infection&#xD;
&#xD;
          -  Patients with GERD (Gastro esophageal reflux disease)&#xD;
&#xD;
          -  Patients with a history of peptic (stomach or duodenal) ulcer disease&#xD;
&#xD;
          -  Patients on Warfarin or anti-platelet drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcia R. Cruz-Correa, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Puerto Rico Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Puerto Rico Comprehensive Cancer Center</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <results_reference>
    <citation>Cruz-Correa M, Hylind LM, Marrero JH, Zahurak ML, Murray-Stewart T, Casero RA Jr, Montgomery EA, Iacobuzio-Donahue C, Brosens LA, Offerhaus GJ, Umar A, Rodriguez LM, Giardiello FM. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology. 2018 Sep;155(3):668-673. doi: 10.1053/j.gastro.2018.05.031. Epub 2018 May 23.</citation>
    <PMID>29802852</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>November 18, 2020</results_first_submitted>
  <results_first_submitted_qc>November 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 16, 2020</results_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Puerto Rico</investigator_affiliation>
    <investigator_full_name>Marcia R. Cruz-Correa, MD, PhD</investigator_full_name>
    <investigator_title>Director of Gastrointestinal Oncology</investigator_title>
  </responsible_party>
  <keyword>Familial Adenomatous Polyposis (FAP)</keyword>
  <keyword>Curcumin</keyword>
  <keyword>Colorectal polyps</keyword>
  <keyword>Duodenal polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from September 2011 to November 2016 at the Johns Hopkins Hospital and the University of Puerto Rico Medical Sciences Campus. Participants were identified and recruited from the Johns Hopkins Polyposis Registry or from the University of Puerto Rico Familial Colorectal Cancer Registry.</recruitment_details>
      <pre_assignment_details>Absence of effective birth control; pregnancy; WBC &lt; 3500/ml; platelet &lt; 100,000/ml, BUN &gt; 25 mg/dl, Creat &gt; 1.5 mg/dl; malignancy; unwillingness to discontinue NSAIDs; active reflux; hx of peptic ulcer; active bacterial infection; use of warfarin or antiplatelets; allergy to curcumin. 3 month washout period for individuals taking NSAIDs, curcumin, turmeric, aspirin, calcium, vitamin D, green tea or polyphenol E</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Curcumin</title>
          <description>Curcumin&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (sugar pills)&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>noncompliance, prophylactic surgery, inc</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Curcumin</title>
          <description>Curcumin&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (sugar pills)&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="1"/>
                    <measurement group_id="B2" value="38.7" spread="1"/>
                    <measurement group_id="B3" value="41.6" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Polyps</title>
        <description>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number in patients with FAP.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pills)&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Polyps</title>
          <description>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp number in patients with FAP.</description>
          <units>Number of Polyps</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="12.1" upper_limit="33.1"/>
                    <measurement group_id="O2" value="22.6" lower_limit="9.93" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Size of Polyps</title>
        <description>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp size in patients with FAP.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Curcumin</title>
            <description>Curcumin&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (sugar pills)&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Polyps</title>
          <description>To determine in a randomized, double-blinded, placebo-controlled study the tolerability and efficacy of curcumin to regress intestinal adenomas by measuring duodenal and colorectal/ileal polyp size in patients with FAP.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.8" upper_limit="2.8"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.5" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Curcumin</title>
          <description>Curcumin&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (sugar pills)&#xD;
Calcumin (Curcumin): Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).&#xD;
Risk Factor Questionnaire: Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.&#xD;
Blood samples: Three tubes of blood at visits 0, 4 and 12 months.&#xD;
Biopsies (Sigmoidoscopy): Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.&#xD;
Biopsies (Upper endoscopy): Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Marcia Cruz-Correa</name_or_title>
      <organization>University of Puerto Rico Medical Sciences Campus</organization>
      <phone>787-758-2525 ext 1722</phone>
      <email>marcia.cruz1@upr.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

